Enterococcus Faecalis Infection Management

First-Line Treatment Selection

The Infectious Diseases Society of America recommends ampicillin 2 g IV every 4-6 hours as the gold standard for most E. faecalis infections when susceptibility is confirmed (MIC ≤8 mg/L) 1, 2
High-dose amoxicillin 1000 mg orally three times daily is appropriate for outpatient treatment of less severe infections, particularly chronic prostatitis, as it achieves MICs two to four times lower than penicillin G against enterococci 3
Piperacillin-tazobactam can be used as an alternative when broader coverage is needed for polymicrobial intra-abdominal infections, though it should be tailored once cultures confirm E. faecalis 1, 2
For patients with valvular heart disease, prosthetic materials, or immunocompromised status, empiric anti-enterococcal coverage is mandatory even before culture confirmation 1, 2

Vancomycin 30 mg/kg/day IV in 2 divided doses is the primary alternative for patients with severe penicillin allergy or ampicillin-resistant strains 1, 2, 3
Reserve vancomycin for true penicillin allergy due to antimicrobial stewardship concerns 3
Linezolid 600 mg IV/PO every 12 hours is the preferred agent for VRE infections, with proven clinical efficacy and excellent tissue penetration 4
Daptomycin 8-12 mg/kg/day IV is an alternative for VRE, though it may have less prostatic penetration for genitourinary infections 4

Amoxicillin 500 mg orally every 8 hours is ideal for uncomplicated cystitis 3
Anti-enterococcal coverage is mandatory when enterococci are recovered from healthcare-associated infections 1, 2
For community-acquired biliary infections, anti-enterococcal coverage is NOT required unless the patient is immunosuppressed, as pathogenicity has not been demonstrated in immunocompetent hosts 1, 2
Coverage is essential for patients with postoperative infections, prior cephalosporin exposure, or prosthetic materials 1, 2
High-dose amoxicillin 1000 mg three times daily for 4-6 weeks is recommended for chronic prostatitis, targeting trough concentrations of 40-80 mg/L to overcome the blood-prostate barrier 3, 5

Do not use cephalosporins alone for enterococcal coverage—they have no intrinsic activity against enterococci despite in vitro synergy when combined with ampicillin 1, 2
Avoid empiric coverage for vancomycin-resistant E. faecium unless the patient is at very high risk (liver transplant with hepatobiliary source, known VRE colonization) 1, 2